Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt, Inc. (NASDAQ: ADTX) is an innovative life sciences company specializing in the development and commercialization of immune monitoring and modulation technologies. The company's mission is to advance humanity into the 'age of immunity' by decoding and harnessing the immune system for better health outcomes.
Aditxt's portfolio includes two flagship programs: Adimune™ and AditxtScore™. Adimune™ is focused on creating immunotherapies that promote tolerance to transplanted organs, while AditxtScore™ offers advanced immune monitoring solutions. The company's products and technologies aim to address critical medical needs, such as preventing organ transplant rejection, managing autoimmune diseases, and providing personalized diagnostic insights.
Recently, Aditxt has expanded its reach by acquiring strategic assets and forming new partnerships. Notably, its subsidiary Pearsanta, Inc. acquired MDNA Life Sciences’ proprietary early disease and cancer detection platform, including Mitomic™ technology. This acquisition enhances Aditxt's capabilities in precision diagnostics and early disease detection, with applications spanning various cancers and other serious health conditions.
Financially, Aditxt has shown robust growth through strategic acquisitions and innovative product development. The company’s commitment to enhancing patient outcomes through cutting-edge technologies is evident in its expanding product line and growing market presence.
For more information, visit the official website at aditxt.com.
Aditxt (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, has engaged Dominari Securities as lead underwriter for its planned IPO, targeted for H2 2025. The IPO aims to support Pearsanta's commercial launch of early cancer detection technology in the U.S. and internationally.
Pearsanta is developing a non-invasive blood-based test using proprietary Mitomic® Technology, which utilizes mitochondrial DNA deletions as biomarkers for disease detection. The company is currently advancing clinical validation, including a randomized controlled study of the Mitomic Prostate Test (MPT).
The company has submitted two research proposals: a $2.3M proposal to evaluate MPT's role in reducing unnecessary biopsies, with a decision expected in H1 2025, and a $1.1M proposal for validating the Mitomic Ovarian Test (MOT), which was not funded. IPO proceeds will fund the U.S. launch of Laboratory Developed Tests and drive global commercialization through partnerships and regulatory approvals.
Aditxt (NASDAQ: ADTX) has announced a virtual Fireside Chat scheduled for Friday, February 21, 2025, at 11:30 AM Eastern Time. CEO Amro Albanna will lead the session, providing updates on key corporate developments and the company's pipeline.
The discussion will focus on two main areas: Adimune, a subsidiary working on autoimmune conditions including Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome, and Pearsanta's early cancer detection program and its planned IPO for 2025.
Participants can submit questions via email to engagement@aditxt.com by February 20th at 5:00 PM ET. Registration is available through the provided Zoom webinar link.
Aditxt (NASDAQ: ADTX) announced its Board of Directors has approved exploring an Initial Public Offering (IPO) for its subsidiary, Pearsanta, targeted for 2025. Pearsanta, a precision diagnostic company, specializes in early cancer detection through its proprietary Mitomic® Technology platform.
The proposed IPO aims to provide resources for Pearsanta's growth and expand its market presence globally. The company focuses on developing and commercializing early cancer detection solutions to support healthcare professionals in providing earlier and more accurate diagnoses.
This strategic move aligns with Aditxt's mission to accelerate promising health innovations and positions Pearsanta for a successful global launch of its cancer detection platform.
Evofem Biosciences (EVFM) reported Q3 2024 financial results, highlighting a 31% improvement in operating loss to $2.4 million compared to $3.6 million in Q3 2023. Net product sales decreased 12% to $4.5 million. The company acquired global rights to SOLOSEC, a single-dose oral antibiotic, and licensed Phexxi commercial rights in the Middle East. Total operating expenses decreased 20% to $6.9 million. Aditxt invested $5.0 million in Evofem since May 2024, including $1.3 million in Q3 and $2.7 million in October 2024.
Aditxt (NASDAQ: ADTX) announced a significant milestone in its acquisition plans for Appili Therapeutics (TSX: APLI; OTCPink: APLIF). At a special meeting, Appili's shareholders voted overwhelmingly in favor of a plan of arrangement that would allow Aditxt to acquire all issued and outstanding Class A common shares of Appili. This development marks a important step forward in Aditxt's strategy to expand its healthcare innovation platform.
Evofem Biosciences (OTCQB: EVFM) has secured voting agreements with Series E-1 stockholders and convertible noteholders to support its proposed merger with Aditxt's subsidiary Adifem. This follows Aditxt's recent $2.28 million investment in Evofem through Series F-1 convertible preferred stock, completing their total $5.0 million commitment since May 2024. The merger's closing conditions include majority shareholder approval and Aditxt raising approximately $17 million, with $15.2 million needed to satisfy Evofem's senior secured noteholder. The capital received has enabled Evofem to acquire SOLOSEC® and support Phexxi® initiatives targeting GLP-1 users.
Aditxt (NASDAQ: ADTX) has announced a significant development regarding its target acquisition, Appili Therapeutics (TSX: APLI; OTCPink: APLIF). The U.S. Food and Drug Administration (FDA) has provided positive feedback on the development strategy for ATI-1801, Appili's topical antiparasitic product. This feedback aligns with the requirements for the New Drug Application (NDA) submission.
Aditxt (NASDAQ: ADTX) has announced a virtual fireside chat on October 28, 2024, at 11:30 AM ET, featuring Aditxt CEO Amro Albanna, Evofem CEO Saundra Pelletier, and moderated by Dr. Drew Pinsky. The event will focus on:
- Aditxt's acquisition of Evofem
- Post-acquisition plans for Evofem
- Aditxt's approach to accelerating innovations
The chat will highlight Evofem's evolution into a multi-product women's health franchise, including the re-launch of Solosec® and the planned launch of the Mitomic Endometriosis Test (MET™) in mid-2025. Aditxt estimates it will require $19.3 million to fund the Evofem acquisition, including $1.8 million for merger consideration and $2.28 million for additional Evofem stock purchase by October 31, 2024. An additional $15.2 million is needed to satisfy Evofem's Senior Secured Note at closing.
Aditxt (NASDAQ: ADTX) announced that Appili Therapeutics (TSX: APLI; OTCPink: APLIF) will hold a special meeting on November 6, 2024, for shareholders to vote on Aditxt's proposed acquisition. Appili's board recommends voting in favor. Appili has raised CAD $100M for developing infectious disease and biodefense therapeutics. Its portfolio includes:
1. LIKMEZ™: FDA-approved liquid antibiotic
2. ATI-1701: Tularemia vaccine with $14M in funding
3. ATI-1801: Topical treatment for cutaneous leishmaniasis
Two programs may be eligible for FDA Priority Review Vouchers. The acquisition aims to expand Aditxt's reach in addressing infectious diseases and public health challenges.
Aditxt (NASDAQ: ADTX) has announced a stakeholder update and Q&A session scheduled for Friday, October 11, 2024, at 11:30 AM EDT. CEO Amro Albanna will lead the session, covering:
- Company overview and updates on Evofem and Appili transactions
- Current programs in immune and precision health
- Year-end roadmap for 2024
- Q&A segment addressing pre-submitted questions
Aditxt operates two programs focused on immune health and precision health, with plans to introduce two additional programs in public health and women's health. The company has entered into agreements with Appili Therapeutics and Evofem Biosciences for these new programs. Aditxt's innovation platform aims to accelerate promising health innovations through collaboration with research institutions, industry partners, and shareholders.
FAQ
What is the current stock price of Aditxt (ADTX)?
What is the market cap of Aditxt (ADTX)?
What is Aditxt, Inc.'s core business?
What are the main products offered by Aditxt?
What recent acquisitions has Aditxt made to enhance its capabilities?
What is the significance of Aditxt's Adimune™ program?
How does AditxtScore™ contribute to the company's mission?
What is Mitomic™ technology, and how does it benefit Aditxt?
What financial achievements has Aditxt made recently?
Who are Aditxt's target customers?
How does Aditxt's strategic acquisition align with its mission?
Where can I learn more about Aditxt, Inc.?
